Table 2.
Studies reporting incidence of hepatocellular carcinoma following post-sustained virological response in chronic hepatitis C patients treated using direct-acting antiviral therapy (adapted from Baumert et al., 2017 [49]). Prospective studies are indicated using bold text.
| Reference | Country | N | Follow-Up (Months) | Males (%) | Age | Cirrhosis (%) | Post-SVR HCC (%) * |
|---|---|---|---|---|---|---|---|
| ANRS (2016) [42] | France | 189 | 2.2 | 78.0 | 62 | 80.0 | 0.7 |
| ANRS (2016) [42] | France | 13 | 1.8 | 85.0 | 61 | 100.0 | 1.1 |
| ANRS (2016) [42] | France | 314 | - | 82.0 | 61 | 15.6 | 2.2 |
| Cardoso (2016) [66] | Portugal | 54 | 1.0 | 76.0 | 59 | - | 7.4 |
| Cheung (2016) [32] | UK | 317 | 1.3 | - | 54 | 80.1 | 5.4 |
| Conti (2016) [31] | Italy | 344 | 0.5 | 60.1 | 63 | 11.3 | 3.2 |
| Conti (2016) [31] | Italy | 59 | 0.5 | 67.8 | 72 | 16.9 | 28.8 |
| Kobayashi (2016) [58] | Japan | 77 | 4.0 | 44.2 | 63 | 29.9 | 3.0 |
| Kozbial (2016) [34] | Austria | 19 | - | 73.7 | - | 73.7 | 50.0 |
| Minami (2016) [60] | Japan | 27 | - | 67.0 | 71 | 0 | 29.8 |
| Petta (2016) [65] | Italy | 58 | 1.5 | 69.0 | 66 | 4.0 | 26.3 |
| Reig (2016) [30] | Spain | 58 | 0.5 | 69.0 | 66 | 8.6 | 27.6 |
| Calleja (2017) [67] | Spain | 1567 | 53.7 | 60 | 46.7 | 0.9 | |
| Nagata (2017) [43] | Japan | 752 | 1.8 | 45.0 | 69 | - | 3.3 |
| Kanwal (2017) [46] | US | 22,500 | 2.0 | 96.7 | 62 | 68.7 | 0.9 |
| Kobayashi (2017) [58] | Japan | 528 | 7.3 | 58.4 | 54 | 2.2 | |
| Mettke (2017) [68] | Germany | 158 | 1.2 | 55.0 | 59 | 100.0 | 2.9 |
| Petta (2017) [65] | Italy | 58 | 1.5 | 69.0 | 66 | - | 10.8 |
| Calvaruso (2018) [69] | Italy | 2249 | 1.1 | 56.9 | 65 | - | 3.0 |
* Overall reported rates of HCC following SVR during the follow-up period.